Stocks Health care SCTX
NASDAQ · Health careScribe Therapeutics, Inc. (SCTX)
At June 30, 2026 it held $35.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on September 2, 2026.
Key facts about Scribe Therapeutics, Inc.
- Net worth
- Scribe Therapeutics, Inc. has a market value (market cap) of $269.9M at the latest share price. A company's "net worth" usually means this market value or the shareholders' equity on its balance sheet.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on September 2, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
What Scribe Therapeutics, Inc. does
Scribe Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker SCTX.
Earnings: every quarter and the next report date
Latest SEC filings
What Scribe Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 2, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 61% to $1.9M versus the same quarter last year; diluted EPS -$2.62 versus -$4.08.
- September 2, 2026
- August 3, 2026Passive stake (5% or more) SCHEDULE 13G
- July 30, 2026Activist stake (5% or more) SCHEDULE 13D
- July 29, 2026Activist stake (5% or more) SCHEDULE 13D
- July 27, 2026
- July 27, 2026
- July 23, 2026Form S-1MEF filing S-1MEF
- July 20, 2026
- July 10, 2026
Insider trades
What the people running Scribe Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| July 28, 2026 | Aghazadeh BehzadDirector, 10% owner | Boughtindirect | 7,905 | $144.3K |
| July 27, 2026 | Orbimed Advisors LLCDirector | Exercised optionsindirect | 348,825 | - |
| July 27, 2026 | Orbimed Advisors LLCDirector | Boughtindirect | 1,000,000 | $15M |
| July 27, 2026 | Gordon Carl LDirector | Exercised optionsindirect | 348,825 | - |
| July 27, 2026 | Gordon Carl LDirector | Boughtindirect | 1,000,000 | $15M |
| July 27, 2026 | AH Bio Fund II, L.P.10% owner | Exercised optionsindirect | 2,051,742 | - |
| July 27, 2026 | AH Bio Fund II, L.P.10% owner | Exercised optionsindirect | 697,650 | - |
| July 27, 2026 | AH Bio Fund II, L.P.10% owner | Boughtindirect | 333,333 | $5M |
Who owns SCTX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Aghazadeh Behzad13D, may seek influence with 2 related filers | 16.37% | July 30, 2026 |
| RA Capital Management, L.P.13G, passive with 3 related filers | 9.6% | August 3, 2026 |
| Orbimed Advisors LLC13D, may seek influence with 1 related filers | 7.2% | July 29, 2026 |
Largest institutional holders
Insiders
7 insiders reported holding 8,779,493 shares in total, about $146.4M at the last price.
| Holder | Shares |
|---|---|
| Aghazadeh BehzadDirector, 10% owner | 3,088,8883,088,888 held indirectly |
| AH Bio Fund II, L.P.10% owner | 2,385,0752,385,075 held indirectly |
| Gordon Carl LDirector | 1,348,8251,348,825 held indirectly |
| Orbimed Advisors LLCDirector | 1,348,8251,348,825 held indirectly |
| Doudna Jennifer A10% owner | 603,547 |
| Lucas SvetlanaChief Business Officer | 3,0003,000 held indirectly |
| Parrot DavidChief Financial Officer | 1,3331,333 held indirectly |
Questions about SCTX
What does Scribe Therapeutics, Inc. do?
Scribe Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as SCTX. Its shares trade on NASDAQ under the ticker SCTX.
What is Scribe Therapeutics, Inc.'s net worth?
Scribe Therapeutics, Inc. has a market value (market cap) of $269.9M at the latest share price. A company's "net worth" usually means this market value or the shareholders' equity on its balance sheet.
When did Scribe Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on September 2, 2026. It covers the period to June 30, 2026.
Similar companies
Compare SCTX with
Follow SCTX
Get an email when Scribe Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Scribe Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.